Table III.3: States Reporting Whether Anticipatory Compounding is Authorized or Allowed in Their State
  Anticipatory compounding authorized or allowed
State Yes, for both sterile and nonsterile compounding Yes, for sterile compounding only Yes, for nonsterile compounding only No No response
Alabama ✓        
Arizona ✓        
Arkansas         ✓
California ✓        
Colorado ✓        
Connecticut ✓        
Delaware       ✓  
District of Columbia       ✓  
Florida ✓        
Georgia ✓        
Guam       ✓  
Hawaii       ✓  
Idaho ✓        
Illinois ✓        
Iowa ✓        
Kansas ✓        
Kentucky ✓        
Louisiana ✓        
Maine ✓        
Maryland         ✓
Massachusetts ✓        
Michigan ✓        
Minnesota ✓        
Mississippi       ✓  
Missouri ✓        
Montana ✓        
Nebraska ✓        
Nevada ✓        
New Hampshire       ✓  
New Jersey ✓        
New Mexico     ✓    
New York       ✓  
North Carolina ✓        
North Dakota ✓        
Ohio ✓        
Oklahoma ✓        
Oregon ✓        
Pennsylvania       ✓  
Rhode Island ✓        
South Carolina ✓        
South Dakota ✓        
Tennessee ✓        
Texas ✓        
Utah ✓        
Vermont ✓        
Virginia ✓        
Washington ✓        
West Virginia ✓        
Wisconsin ✓        
Wyoming ✓        

Source: GAO survey of state pharmacy regulatory bodies, survey question 14. | GAO-17-363SP
Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.
Anticipatory compounding is the creation of a drug product prior to receipt of an individual patient prescription in anticipation of receiving prescriptions based on historical prescribing patterns.